Roche PD-1 inhibitor liver cancer combination therapy was recognized by the FDA as a breakthrough therapy

Share This Post

The Swiss Roche Group announced yesterday that TECENTRIQ® (atezolizumab) in combination with Avastin® (bevacizumab) has been approved by the US Food and Drug Administration (FDA) for breakthrough therapy for initial (first-line) treatment of advanced or metastatic liver Patients with cell carcinoma (HCC).

HCC is the most common type of primary liver cancer . This breakthrough therapy is based on the results of a Phase Ib study on the safety and clinical activity of TECENTRIQ combined with Avastin.

Dr. Sandra Horning, Roche’s chief medical officer and head of global product development, said: Hepatocellular carcinoma, as a malignant tumor, has limited treatment options and is the leading cause of death worldwide. Preliminary data on the treatment of this disease with TECENTRIQ and Avastin is promising. We look forward to cooperating with the health department to bring this highly promising treatment plan to patients with hepatocellular carcinoma as soon as possible.

Breakthrough Therapy Designation (BTD) aims to accelerate the development and review of new drugs for the treatment of serious or life-threatening diseases to ensure that these drugs are approved by FDA as soon as possible to benefit patients. This is not only the 22nd BTD obtained by Roche’s pharmaceutical product line, but also the 3rd BTD obtained by TECENTRIQ.

The Roche Group published data from the Phase Ib study of hepatocellular carcinoma at the American Society of Clinical Oncology (ASCO) annual meeting in June 2018. The results of the study showed that after a median follow-up of 10.3 months, remission was observed in 15 (65%) of 23 evaluable patients.

After a median follow-up of 10.3 months, the median progression-free survival (PFS), duration of remission (DOR), disease progression time (TTP), and overall survival (OS) were not reached. Of the safety-evaluable patients (n = 43), 28% (n = 12) experienced grade 3-4 treatment-related adverse events, and no treatment-related grade 5 adverse events were observed.

Roche has provided additional data in accordance with FDA requirements, and has been granted a breakthrough therapy qualification. After obtaining updated data from follow-up trials, Roche will publish the research results at a future medical conference.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer
Colon cancer

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

The FDA has granted accelerated approval to Adagrasib combined with Cetuximab for treating KRAS G12C-mutated colorectal cancer. This approval is based on promising clinical trial results showing enhanced efficacy of the drug duo. Adagrasib, a KRAS inhibitor, and Cetuximab, an EGFR inhibitor, together target the cancer more effectively, offering new hope for patients with this specific genetic mutation, aiming to improve survival rates and treatment outcomes.

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
Endometrial cancer

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

The USFDA has approved Pembrolizumab combined with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval is based on clinical trial data showing significant improvements in patient outcomes. Pembrolizumab, an immune checkpoint inhibitor, works by enhancing the body’s immune response against cancer cells. This combination therapy offers a new and promising treatment option for patients facing this challenging and often aggressive cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy